Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Oligen is a commercialized dietary supplement ingredient developed through an exclusive partnership between Oleolive and Applied Food Sciences (AFS). It is a standardized olive polyphenol extract concentrated in two key bioactive compounds: oleocanthal and oleacein, which are naturally found in trace amounts in extra virgin olive oil. Oligen functions primarily as a Cyclooxygenase-2 (COX-2) inhibitor, supporting a healthy inflammatory response and providing antioxidant benefits. It is marketed for applications in joint health, cardiovascular support, and healthy aging/longevity. The ingredient is typically administered orally in capsule, tablet, or softgel form, with a standard 400mg dose delivering the polyphenol equivalent of approximately one-quarter cup of premium olive oil. Oligen utilizes proprietary extraction technology to ensure high bioavailability without the need for additional absorption enhancers.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Oligen.